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Abstract
Background: While chromosome 1 is the largest chromosome in the human genome, less than two dozen cases
of interstitial microdeletions in the short arm have been documented. More than half of the 1p microdeletion cases
were reported in the pre-microarray era and as a result, the proximal and distal boundaries containing the exact
number of genes involved in the microdeletions have not been clearly defined.
Results: We revisited a previous case of a 10-year old female patient with a 1p32.1p32.3 microdeletion displaying
syndromic intellectual disability. We performed microarray analysis as well as qPCR to define the proximal and distal
deletion breakpoints and revised the karyotype from 1p32.1p32.3 to 1p31.3p32.2. The deleted chromosomal region
contains at least 35 genes including NFIA. Comparative deletion mapping shows that this region can be dissected
into five chromosomal segments containing at least six candidate genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6, and
PDE4B) most likely responsible for syndromic intellectual disability, which was corroborated by their reduced
transcript levels in RT-qPCR. Importantly, one patient with an intragenic microdeletion within NFIA and an additional
patient with a balanced translocation disrupting NFIA display intellectual disability coupled with macrocephaly.
Conclusion: We propose NFIA is responsible for intellectual disability coupled with macrocephaly, and
microdeletions at 1p31.3p32.2 constitute a contiguous gene syndrome with several genes contributing to
syndromic intellectual disability.
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Background
Interstitial microdeletions of the short arm of chromo-
some 1 are rare and to date at least 19 cases have been
reported [1–17] (Table 1). It is thought that many genes,
which are critical for early development, reside within
the short arm of chromosome 1 [4]. These heterozygous
deletions, in some cases, might have resulted in the
eventual death of the affected individuals [3, 7, 9, 11].
Patients with 1p interstitial microdeletions display a
number of clinical features including intellectual disabil-
ity, craniofacial anomalies, seizures, tooth abnormalities,
urinary tract anomalies, and skeletal, cardiac as well as
limb defects [3, 4, 7, 12, 16, 17].
Revisiting CNV (copy number variation) cases re-
ported during the pre-microarray era is uncommon,
because the patients are deceased or lost to follow-up.
Re-evaluation of earlier cases using microarray analysis,
however, provides more accurate information on the
candidate genes contained within the CNV regions. Fur-
thermore, it also allows monitoring of any changes in
the patient’s clinical features over time [18]. More than a
decade ago, an apparent interstitial microdeletion at
1p32.1p32.3 was reported in a 10-year old girl with
delayed psychomotor development and facial dysmorph-
ism. This de novo structural chromosomal rearrange-
ment was detected by karyotype analysis alone followed
by fluorescent in situ hybrization (FISH) without defin-
ing the exact size and location of the microdeletion [10].
Here we revisited this proband to revise the karyotype
and to define the size of this microdeletion by molecular
analysis. From molecular dissection of our case with six
published cases of microdeletions, a balanced transloca-
tion, and seven unpublished DECIPHER cases [23], we
propose that there are at least six chromosomal seg-
ments within this region, and each segment harbors at
least one candidate gene for intellectual disability. We
also determined the transcript levels of six candidate
genes (DAB1, HOOK1, NFIA, DOCK7, DNAJC6 and
PDE4B) for syndromic intellectual disability.
Methods
Case presentation
The proband (DGDP005) is a 23-year-old female with a
history of developmental delay and intellectual disability.
In infancy, developmental milestones were delayed and
she exhibited impaired motor skills (Table 2). The pa-
tient displayed craniofacial anomalies including macro-
cephaly (Fig. 1a, b, d-g), frontal bossing (Fig. 1b) and
low-set ears (Fig. 1d). She was diagnosed with attention
deficit hyperactivity disorder (ADHD), obsessive com-
pulsive disorder (OCD), ocular hypertension (OHT), and
developmental encephalopathy with cognitive impair-
ment (Table 2).
At age 10, her grades were Bs and Cs, but school chal-
lenges warranted special education. She also had difficulty
falling asleep and she took nightly melatonin. She was diag-
nosed with ADHD, hypertonia, and possible sensory inte-
gration difficulties (further details on her phenotype up to
age10 can be found in Zinner and Batanian (2003) [10]).
At 14 years of age, she took the Stanford Binet
Intelligence Scales-Fifth edition (SB5). She had difficulty
staying on a task requiring redirection. Her general cog-
nitive ability was estimated to be in the low average
range with a full scale intelligence quotient (FSIQ) score
of 83 (95 % confidence interval 79–87), suggesting intel-
lectual disability. She received a score of 79 in the non-
verbal reasoning abilities, which is in the borderline
range, and higher than only 8 % of her peers. In verbal
reasoning abilities, she scored 88, which is in the low
average, and just above ~12 % of her peers. Her ability
to solve verbal and nonverbal problems using inductive
or deductive reasoning was average. Her overall thinking
and reasoning was worse than ~87 % of children of her
age. She scored in the low average range for general in-
formation gathering, attention span, and concentration.
Her ability to see patterns, relationships, and spatial ori-
entations among diverse pieces of visual display, as well
as her ability with numbers and numerical problem solv-
ing with word problems or with picture relationships
were borderline.
At age 16, she was found to display OHT and ADHD,
language disability in written language expression as well
as in math calculation and math reasoning. She passed
the vision test scoring 20/10 and 20/20 for the right and
left eye respectively. Her hearing was adequate for the
classroom functioning. She showed significant difficul-
ties in fine motor functions with soft neurological signs.
Overall, the assessment showed that she continued to be
a student with intellectual disability and ADHD.
When she was 18, the patient was re-evaluated by the
child neurology services. She was diagnosed with devel-
opmental encephalopathy with cognitive impairment,
OCD and ADHD. She was treated with fluoxetine and
Adderall for OCD and ADHD, respectively. Some of her
facial dysmorphisms became more evident at age 18,
such as her prominent forehead, narrow nose, and thin
lips (Fig. 1). She still displayed low-set ears (Fig. 1d). At
the age of 22, she was admitted to the hospital and diag-
nosed with subarachnoid as well as intraventricular
hemorrhage with layering in the posterior fossa. She was
also diagnosed with a right anterior communicating ar-
tery aneurysm and continued to show developmental
delay, OCD and ADHD.
Cell culture
Lymphocytes were isolated from the patient’s blood sam-
ples by density gradient centrifugation as we have done
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Table 1 Patients with 1p interstitial microdeletions
Patient Karyotype Source Phenotype Methods and coordinates
1 del(1)(p21p32) [1]a1979 Severe psychomotor retardation, craniofacial
and skeletal anomalies, short stature,
overweight.
Karyotyping
2 del(1)(p22.1p31.2) [2]a1987 Psychomotor retardation, craniofacial and
limb anomalies.
Karyotyping
3 del(1)(p22.1p31.2) [3]a1991 Pt 1 Developmental delay, intellectual disability,
craniofacial anomalies.
Karyotyping
4 del(1)(p22.3p31.3) [3]a1991 Pt 2 Developmental delay, seizures craniofacial
and limb anomalies.
Karyotyping
5 del(1)(p32.3p34.1) [4]a1991 Mental and motor developmental delay,
craniofacial and limb anomalies, hypotonia.
Karyotyping
6 del(1)(p36.1p36.2) [5]a1993 Developmental delay, craniofacial anomalies,
neuroblastoma.
Karyotyping
7 del(1)(p32.1p32.3) [6]a1995 Developmental delay, craniofacial and limb
anomalies.
Karyotyping
8 del(1)(p21p22.3) [7]a1997 Craniofacial and limb anomalies, congenital
heart disease, rib abnormalities.
Karyotyping
9 del(1)(p34.1p34.3) [8]a1999 Pt 1 Severe learning disability, attention deficit
disorder (ADD), craniofacial anomalies.
Karyotyping and FISH with probes specific
for chromosome 1 (COATA-SOMETM1,
p5205-DG.5)
10 del(1)(p34.1p34.3) [8]a1999 Pt 2 Attention deficit hyperactivity disorder (ADHD),
craniofacial anomalies, disturbed behaviors.
Karyotyping and FISH with probes specific
for chromosome 1 (COATA SOMETM1,
p5205-DG.5)
11 del(1)(p32.1p32.3) [9]a 2002 Pt 1 Global developmental delay, craniofacial
anomalies, absence of corpus callosum,
type I Chiari malformation, tethered cord.
Karyotyping and FISH with probes specific
for whole chromosome painting
12 del(1)(p32.1p32.3) [9]a2002 Pt 2 Intraventricular hemorrhage, seizures, thin
corpus callosum, limb anomalies
Karyotyping and FISH with probes specific
for whole chromosome painting
13 del(1)(p32.1p32.3) [10]a2003 Delayed psychomotor development,
craniofacial anomalies
Karyotyping and FISH using whole
chromosome 1 painting probe (wcp1)
14 del(1)(p36) [11]a2004 Craniofacial anomalies, moderate intellectual
disability, seizures.
FISH with TelVysion 1p (Vysis), P5124
(Oncor), a YAC 273d11 (CEPH)
15 del(1)(p31.3p32.2) [12] 2010 Craniofacial anomalies, hypoplasia of corpus
callosum, ventriculomegaly, hypotonia
105K Oligoarray CGH & BAC array CGH,
4.93 Mb deletion, 1p32.2p31.3
(chr1:58,193,565-63,125,273)X1 dn, hg19
16 del(1)(p36.3) [13]a 2010 Prader-Willi like features. MLPA, FISH with BAC probes, real-time
q-PCR
17 del(1)(p31.1p32.2) [14] 2014 Craniofacial anomalies, partially hypoplastic
corpus callosum, mild ventriculomegaly,
intraparenchymal hemorrhages, cerebral palsy.
SNP- microarray (SNP-CMA), 22.9 Mb
deletion (chr1:55,113,975-77,992,492)X1,
hg19
18 del(1)(p36.3) [16] 2008 Developmental delay, facial dysmorphisms,
neuroblastoma
MLPA, 244 K oligo microarray, a deletion
of 1.59 Mb at 1p36.3 and a duplication of
3.26 Mb at 1p36.3 (1,741,058-5,004,693)X3,
hg18, FISH with Vysis 1p36 and BACs
19b del(1)(p31.3p32.1) [17] 2007 Abnormal corpus callosum, Ventriculomegaly,
developmental tethered spinal cord, Chiari I
malformation
array Comparative genomic hybridization
(aCGH)
20 del(1)(p32.1p32.3) [22] 2015 Microcephaly, urogenital anomalies, hearing
loss, choanal atresia.
SNP microarray, 6.4 Mb deletion
(chr1:54,668,618-61,113,264)X1,
hg19, FISH with BACs
DCP274057 partial C-terminal
duplication of NFIA




DECIPHER 117 kb deletion at 1p31.3, phenotype not
available
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previously [19]. Lymphoblastoid cell line (LCL) was gen-
erated from the patient’s blood in order to determine the
transcript levels of genes of interests.
Genomic DNA extraction and microarray
Genomic DNA was extracted from the patient’s blood
samples using a standard phenol-chloroform protocol
with minor modifications. The human genome 244 K
array (Agilent technologies, G4411B) was used to detect
copy number variation as described previously in Miller
et al. (2012) [20].
Real-Time genomic qPCR and RT-qPCR
Primers targeting regions encompassing the proximal
and distal deletion breakpoints were designed for qPCR.
Primer pairs were first evaluated by determining the pri-
mer efficiency using a serial dilution of genomic DNA as
template.
Primers were also designed against exonic regions of
genes of interests for RT-qPCR. Total RNA was isolated
from cell lines established from patient DGDP005 using
the RNeasy Plus Mini kit (Qiagen) following the manu-
facturer’s instructions. cDNA was synthesized from 1 μg
of total RNA using the RevertAid First cDNA Synthesis
Kit (Thermo Scientific) according to the manufacturer’s
protocol. All Real-Time qPCR reactions were carried out
using 2 μl of sample, 10 ml of Fast Essential DNA Green
Master (Roche) and 2.5 μM primers in a total reaction
volume of 20 μl.
Results
Microarray
Microarray performed on genomic DNA derived from
patient DGDP005 revealed a 9.45 Mb microdeletion at
1p31.3p32.2 (chr1: 57,633,718- 67,087,056, GRCh38/
hg38). The deleted chromosomal region contains at least
35 genes, including NFIA (Fig. 2).
Comparative deletion mapping
We compared all clinical features displayed by
DGDP005 with five previously reported microdeletion
cases namely, Campbell et al. (2002) [9], Koehler et al.
(2010) [12], Ji et al. (2014) [14], Lu et al. (2007) [17], Rao
et al. (2014) [21], Kehrer et al. (2015) [22] at 1p31.1p32.2
overlapping our microdeletion at 1p31.3p32.2, as well as
one translocation case involving the NFIA gene in Lu et
al. (2007) [17] (Table 3). We also compared the microde-
letion in DGDP005 to seven cases from the DECIPHER
database [24] (Fig. 2, Table 1). The refined candidate
gene region represented by DCP300407 and proximal
breakpoint of DCP276512 was depicted in two orange
lines (Fig. 2), while two vertical black lines depict nar-
rowed candidate region among 5 small CNVs including
4 DCP cases and a microdeletion of Rao et al. (2014)
[21]. We examined the functions of all genes involved in
the microdeletion by reviewing the literature to highlight
candidate genes that could contribute to phenotypes
observed in DGDP005 (Table 4). Patient DGAP174 of
Lu et al. (2007) was not included in determining
genotype-phenotype relationships (Table 3), because
of an accompanying chromosomal translocation t(1;3)
(p31.1; q25.1) [17].
Real-Time qPCR
We performed qPCR to refine the flanking coordinates
of the deletion breakpoints. qPCR assays using primers
designed from the DAB1 gene revealed that the distal
deletion breakpoint is located between DAB1 exon 1
and its 5′-UTR. The SLC35D1 gene was found to be
completely deleted as predicted by microarray (Figs. 2
Table 1 Patients with 1p interstitial microdeletions (Continued)
DCP285169 intragenic duplication
of NFIA
DECIPHER 419 kb duplication paternally inherited at
1p31.3, additional 2.07 Mb maternal
deletion at 15q13, delayed fine motor
development, expressive language delay,




DECIPHER 229 kb deletion at 1p31.3, intellectual
disability, macrocephaly
DCP300407 del(1)p32.1 DECIPHER 281 kb deletion at 1p32.1, cognitive
impairment
DCP264827 del(1)p31.3 DECIPHER 5.43 Mb deletion at 1p31.3, abnormally
folded helix, ADHD, constipation, flat
forehead, global developmental delay,
hypothyroidism, malar flattening
DCP276512 del(1)p31.3p32.1 DECIPHER 8.83 Mb deletion at 1p31.3-1p32.1,
delayed speech and language
a Microdeletions without genomic coordinates reported in the pre-microarray era. Pt denotes patient
bPt 19 has additionally a chromosomal translocation 46,XY,t(1;3)(p22;q21)dn
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and 3). The proximal deletion breakpoint was found to
reside in the intergenic region between gene SLC35D1
and uncharacterized gene C1orf141 (Figs. 2 and 3).
RT-qPCR
Expression analysis of six genes of interest by RT-qPCR
revealed that the transcript levels of NFIA, DAB1 and
DNAJC6 were markedly reduced in the patient relative
to a healthy white female control (Fig. 4). Transcripts
derived from HOOK1 and DOCK7 were reduced
approximately by half, while PDE4B transcripts de-
creased moderately (Fig. 4).
Discussion
The female patient (DGDP005) examined in this study
was first reported as a 10-year old girl possessing a rare
1p32.1p32.3 microdeletion [10]. Characterization of the
microdeletion in the patient by microarray allowed the
refinement of the microdeletion from 1p32.1p32.3 to
1p31.3p32.2. The health condition of DGDP005 has
Table 2 Timescale of DGDP005’s medical evaluations as well as her clinical features
Age Evaluation Clinical features
<5 years Pediatrician - Crawling, sitting, walking and attaining language milestones delayed
- Craniofacial anomalies including macrocephaly
- Problematic motor skills.
~10 years Developmental pediatrician - Special education implemented in curriculum
- Difficulty falling asleep and treatment with melatonin
- ADHD
- Hypertonia.
- Possible sensory motor difficulties.
14 years Standford Binet Intelligence Scales-Fifth
edition (SB5)
- Difficulty staying on the task and needed to be redirected from time to time
- Overall thinking and reasoning at ~13 percentile.
- Borderline nonverbal reasoning abilities
- Verbal reasoning at ~12 percentile
- Verbal and nonverbal problem solving at ~ 58 percentile
- Ability to gather information at ~ 18 percentile
- Numerical problem solving at ~7 percentile.
- Borderline visual display abilities
- Ability to maintain attention at ~13 percentile.
- Full scale quotient of 83 (95 % confidence interval 79–87) suggesting intellectual disability.




- Language disability in written language expression
- Disability in math calculation and reasoning
- Difficulties in fine graph motor functions with soft neurological signs.
- Continues to be a student with disability
18 years Child neurology services - Developmental encephalopathy
- Cognitive impairment
- OCD as well as ADHD
-Treatment with fluoxetine (aka Prozac10 mg) and Adderall (15 mg)
- More pronounced facial dysmorphisms including prominent forehead, low-set ears,
narrow nose thin lips
22 years Admitted to emergency - Diagnosed with intraventricular hemorrhage with layering in the posterior fossa.
- Right anterior communicating artery aneurysm
- Developmental delay, OCD and ADHD
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been monitored regularly since the first few months of
her life. Psychomotor delay and craniofacial anomalies
were apparent since infancy [10]. During the follow-up,
she has continued to display developmental delay and as
a result, special education has been implemented in her
curriculum. Craniofacial anomalies such as macroceph-
aly and frontal bossing became more pronounced over
time, suggesting the involvement of culprit gene(s) in
continuous skull development since infancy [10]. Add-
itional features such as OCD and intraventricular
hemorrhage were also observed after the age of ten, em-
phasizing the importance of follow-up.
We have now determined the size of the deletion in
DGDP005 by microarray and refined the locations of the
flanking deletion breakpoints by qPCR (Figs. 2 and 3). The
deleted region is at least 9.45 Mb encompassing more
than 35 annotated genes including NFIA [17]. Only four
smaller-sized heterozygous microdeletions (Rao 2014, Lu
2007, Koehler 2010 and Kehrer 2015) have been reported
so far within this interval (Fig. 2). The patient of Koehler
et al. (2010) [12] had a 1p31.3p32.2 microdeletion while
another patient DGAP174 of Lu et al. (2007) had a dele-
tion at 1p31.3p32.1 with additional translocation, 46,XY,
t(1;3)(p31.1;q25.1) [17]. The patient of Rao et al. (2014)
had a small microdeletion spanning exons 4–9 within
NFIA [21]. The distal part of the microdeletion of Kehrer
overlaps with the proximal part of DGDP005 and the
more refined candidate region is represented by
DCP300407. Two larger microdeletions of two half sib-
lings (DGAP205-1 and DGAP205-1S) (Table 3)
reported in Campbell et al. (2002) and a patient de-
scribed in Ji et al. (2014) encompassing the whole
chromosomal region deleted in DGDP005, have also
previously been published [9, 14] (Fig. 2).
Haploinsufficiency of the NFIA gene is expected to
cause an abnormal corpus callosum, ventriculomegaly or
hydrocephalus, developmental delay, tethered spinal
cord, Chiari I malformation, seizures, urinary tract de-
fects, and craniofacial anomalies [17, 21]. Furthermore,
disruption of nfia in mouse results in severe develop-
mental defects including agenesis of corpus callosum, se-
vere communicating hydrocephalus, female subfertility,
and male sterility [24]. Five CNV cases (DCDP274057,
DCP260253, DCP285169, DCP288170, Rao 2014) only
had NFIA disrupted (Fig. 2). Among these five DE-
CIPHER cases, DCP288170 with an intragenic deletion
within NFIA, displayed intellectual disability. Although,
this phenotype was not emphasized in Lu et al. (2007)
[17], DGAP104 with a balanced translocation of
t(1;20)(p31.3;q13.31) disrupting NFIA at 1p31.3 break-
point (Table 3) also displayed intellectual disability
(global IQ score of 52). Patient DCP274057 presents
with global developmental delay while DCP285169
displays expressive and receptive language delay. The pa-
tient reported in Rao et al. (2014) with a deletion involv-
ing exons 4–9 of NFIA was only 8 years-old, and had
not yet been evaluated intellectual disability [21]. The
aforementioned patients clearly suggest that disruption
of NFIA is likely to cause intellectual disability, or cogni-
tive deficits. Indeed, the NFIA transcript levels were
Fig. 1 Phenotypic features of DGDP005. a Facial and head appearance including macrocephaly and upper body picture at 4 years (b) Lateral
facial feature of 4 years of age showing frontal bossing (c) Full body picture as a 7 years old (d) upper body and head appearance presenting
with macrocephaly at 12 (e) 13 (f) 16 and (g) 18 years of age
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markedly reduced in DGDP005 (Fig. 4) suggesting that
NFIA may be contributing to syndromic intellectual
disability.
Notably, four microdeletion patients namely Campbell
et al., 2002 [9], Koehler et al., 2010 [12], Ji et al., 2014
[14] and DGDP005 had in common macrocephaly
(Table 3). Importantly, a balanced translocation patient
DGAP104, in whom NFIA is disrupted at 1p31.3 [17]
also had macrocephaly. Furthermore, the patient re-
ported in Rao et al. (2014) [21] with a smaller microdele-
tion within NFIA also had macrocephaly (Fig. 2 and
Tables 1 and 3). Collectively, these findings underscore
that the haploinsufficiency of NFIA is sufficient to cause
intellectual disability and macrocephaly, two of the core
phenotypic features of del (1)(p31.3p32.2) microdeletion
syndrome.
Fig. 2 Comparative deletion mapping of patients with CNVs at 1p31.3p32.2. The genes located within this interval are displayed. Microdeletions
are represented by solid red bars while microduplications are displayed in blue. Patients with CNVs from the DECIPHER database (Firth et al.,
2009) are denoted by ‘DCP’ followed by the reference number. The sizes of the deleted regions in Rao 2014, Lu 2007 (DGAP174), Koehler 2010,
Kehrer 2015, Campbell 2002 (DGAP205-1), Ji 2014 and seven DECIPHER cases relative to our patient (DGDP005) are displayed. Four CNVs
(DCPP274057, DCP260253, DCP288170, Rao 2014) have only NFIA disrupted implying that it is causative gene in all four patients. Patient
DCP285169 with a 419 kb duplication including the second half of NFIA presents with language delay, impaired social interactions, and delayed
motor development. But he also has an additional 2.07 Mb microdeletion at 15q13. The microdeletion in patient DCP300407 does not include
NFIA, yet the patient displays cognitive impairment, suggesting the likely contribution of HOOK1. Two microdeletions (Ji 2014 and Campbell 2002)
extend beyond the 1p32.2 and 1p31.3 interval. Vertical lines in blue represent the proximal and distal boundaries of the microdeletion in
DGDP005. Two orange lines are refined candidate gene region overlapping eight microdeletions including DCP300407. Two vertical black lines
depict narrowed candidate region among 5 small CNVs [4 DCP cases and patient of Rao et al. (2014)]. Asterisk denotes candidate genes in
this region
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While comparing the clinical features of our patient
with the two half-siblings [9] who have a larger microde-
letion including NFIA, we found that DGDP005 does
not manifest ventriculomegaly, tethered spinal cord,
Chiari I malformation, or urinary tract defects. Similarly,
the patient having a smaller microdeletion encompassing
NFIA [12] displayed only three of the clinical features as
a result of NFIA deletion, namely abnormal corpus callo-
sum, ventriculomegaly and developmental delay. Incom-
plete penetrance may partly explain why all phenotypes
expected from NIFA disruption are not manifested in
the patients with an NFIA deletion (Table 3 and Fig. 2)
[25]. We have not included DGAP174 [17] in the com-
parison because he had a de novo translocation t(1;3)
(p31.1; q25.1)dn in addition to a 2.2 Mb interstitial dele-
tion at 1p31.3-p32.1 (Table 3).
Reviewing phenotypes displayed by patients with micro-
deletions at 1p31.3-1p32.2 enabled identification of at
least 17 clinical features seen across all patients (Table 3).
Because of the putative chromosomal segments with cor-
responding candidate genes for cognitive impairment
within this region, it is obvious that not all phenotypes ob-
served can be attributed to NFIA alone. It is likely that
genes including NFIA in this region are haploinsufficient
thereby contributing to the 17 clinical features observed
across all patients (Table 3) [17]. It supports the idea that
the 1p31.3p32.2 microdeletion may constitute a “chromo-
some syndrome” postulated in Zinner and Batanian
Table 4 Functions of candidate genes possibly contributing to clinical phenotypes observed in patient DGDP005
Gene name Gene symbol Age Association with neuro-developmental
features
Remarks
Nuclear factor I/A NFIA [16] ~2 yrs Abnormal corpus callosum,
ventriculomegaly, hydrocephalus,
developmental delay, tethered
spinal cord, chiari I malformation,
and urinary track defect
Disruption of Nfia in mice result in severe
developmental defects including agenesis
of the corpus callosum, severe communicating
hydrocephalus, neurological defects, male
sterility, female subfertility [24]
[21] 8 yrs
Dab, reelin signal transducer
homolog 1
DAB1 [37] ~7.5 yrs Autism
Hook homolog 1(Drosophila) HOOK1 [23] 5 yrs Cognitive impairment (DCP300407) Cytosolic protein possessing a conserved
N-terminal domain that binds to microtubules.
Interacts with CLN3, the causative gene for
autosomal recessive Batten disease.
Dedicator of cytokinesis 7 DOCK7 [38] 5–7 yrs Epileptic encephalopathy, dysmorphic
features and intellectual disability
DOCK7 plays a role in neural development
DnaJ (Hsp40) homolog,
C, member 6
DNAJC6 [31] 17–44 yrs Parkinson disease Subfamily -
Phosphodiesterase 4B,
cAMP-specific
PDE4B [35] NS Schizophrenia -
NS; Not stated
Fig. 3 Refining the deletion breakpoints in DGDP005 by qPCR. The 5′-UTR of the DAB1 gene is deleted while its first exon is intact indicating that
the distal deletion breakpoint lies between DAB1 exon 1 and the 5′-UTR. The NFIA gene and SLC35D1 are both completely deleted in our patient.
Two separate loci located in the proximal and distal intergenic region between SLC35D1 and C1orf141 were also assayed by qPCR. The distal
intergenic region residing closer to SLC35D1 was found to be contained in the microdeletion, while the proximal intergenic region was intact.
A value close to 1 indicates that the locus is not deleted, while a value near 0.5 shows deletion on another allele
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(2003) [10], which meant to be contiguous gene deletion
syndrome [26]. Recently, Ji et al. (2014) [14] also
postulated the possible involvement of genes other than
NFIA. We have reviewed the functions of all genes within
the 1p31.3p32.2 microdeletion in DGDP005. Molecular
dissection of this region suggests the presence of at least
five chromosomal segments, with six candidate genes for
intellectual disability. Each segment contains DAB1,
HOOK1, NFIA, DOCK7, and DNAJC6 as well as PDE4B,
respectively. We propose six candidate genes (DAB1,
HOOK1, DOCK7, DNAJC6, PDE4B, and NFIA) for the
clinical features such as intellectual disability and OCD
observed in DGDP005, because each of these genes is in-
volved directly or indirectly in neurological disorders
(Table 4).
While HOOK1 interacts with CLN3, the causative
gene for the autosomal recessive Batten disease charac-
terized by visual impairment, gait anomalies, seizures,
dementia and sometimes mental deterioration [27–30],
DNAJC6 has been shown to be implicated in Parkinson
disease [31]. It is noteworthy that Batten disease is also
characterized by progressive neurodegeneration and im-
paired motor skills [32] like Parkinson disease [33, 34].
Furthermore, patient DCP300407 with only HOOK1,
CYP2J2 and C1orf87 deleted (Fig. 2) displays cognitive
impairment [24]. Additionally, PDE4B is implicated in
schizophrenia [35], whereas DAB1 truncated in our pa-
tient is required for synaptic function as well as associa-
tive learning in mice [36], and has been shown to be
associated with autism [37].
Recently, mutation in DOCK7 has been found to be
associated with epileptic encephalopathies, dysmorphic
features and intellectual disability [38]. Interestingly,
DGDP005 displays some of the phenotypes expected
from DOCK7 mutation indicating that DOCK7 may also
contribute to intellectual disability and craniofacial
anomalies in our patient. As is the case for DOCK7, cog-
nitive impairment is an overlapping clinical feature also
produced by disruption in NFIA. This further supports
the hypothesis that deletion at 1p31.3p32.2 constitutes a
contiguous gene deletion syndrome. As expected, the
transcript levels of DOCK7 and HOOK1 was reduced ap-
proximately by half. The level of transcripts of DAB1,
DNAJC6 and PDE4B were also reduced in our patient
relative to a healthy white female control (Fig. 4). The
significant reduction of transcripts of NFIA and two add-
itional genes (DAB1 and DNAJC6) suggests an allele-
specific expression pattern (Fig. 4). This may be due to a
loss of the allele actively transcribed in the microdele-
tion. It is unclear whether the causative effect of each
candidate gene is stoichiometrically contributing to the
manifestation of the phenotype or an effect of one gene
is masked by the effect of other gene when more than
one candidate gene is deleted in a microdeletion. If some
of the candidate genes participate in overlapping mo-
lecular pathways leading to cognitive impairment, the ef-
fect of one gene may be masked by another.
Conclusion
Revisiting patient DGDP005 has allowed us to refine the
flanking proximal and distal breakpoints, enabling us to
compare the clinical phenotypes of DGDP005 to re-
ported cases and unpublished DECIPHER cases. Com-
parative deletion mapping showed that there are at least
six candidate genes including, NFIA, HOOK1, DOCK7,
DAB1, DNAJC6, and PDE4B, that could contribute to
the syndromic or non-syndromic intellectual disability.
Most importantly, the genomic and clinical delineation
result implies NFIA responsible for intellectual disability
coupled with macrocephaly. Smaller-sized microdele-
tions across this interval and rare point mutations in the
genes should reveal a better understanding of the
Fig. 4 Transcript levels of six candidate genes involved in CNVs were determined by RT-qPCR. The level of transcripts of DAB1, NFIA and DNAJC6
were markedly reduced in DGDP005 relative to the healthy white female control. Transcripts derived from HOOK1 and DOCK7 were reduced
approximately by half, while PDE4B transcripts decreased moderately
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pathological role of individual gene residing within this
region. Additionally, expression studies including hap-
loinsufficiency of aforementioned candidate genes in this
interval will provide more insights both on the number
of candidate genes and their impact on this contiguous
gene syndrome.
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